Combined endovascular brachytherapy, sorafenib, and transarterial chemobolization therapy for hepatocellular carcinoma patients with portal vein tumor thrombus

Table 2 Baseline characteristics of propensity-matched patients n (%)

Characteristic	Group A	Group B
	(n = 24)	(n = 24)
Sex
Male	22 (91.7)	23 (95.8)
Female	2 (8.3)	1 (4.2)
Age
≥ 55 yr	14 (58.3)	9 (37.5)
< 55 yr	10 (41.7)	15 (62.5)
Type of tumor
Nodular	21 (87.5)	22 (91.7)
Infiltrative	3 (12.5)	2 (8.3)
HCC maximum diameter
≥ 5 cm	16 (66.7)	17 (70.8)
< 5 cm	8 (33.3)	7 (29.2)
Degree of MPVTT
Stenosis	21 (87.5)	19 (79.2)
Occlusive	3 (12.5)	5 (20.8)
Child-pugh class
A	20 (83.3)	21 (87.5)
B	4 (16.7)	3 (12.5)
ECOG performance status
0/1	20(83.3)	22(91.7)
2	4(16.7)	2(8.3)
Etiology of liver disease
HBV	22 (91.7)	23 (87.5)
Other	2 (8.3)	1 (12.5)
Serum AFP level
≥ 400	12 (50.0)	10 (41.7)
< 400	12 (50.0)	14 (58.3)
Extrahepatic metastasis	1 (3.8)	3 (11.5)

AFP: Alfa-fetoprotein; ECOG: Eastern cooperative oncology group; HBV: Hepatitis B virus; MPVTT: Main portal vein tumor thrombus; HCC: Hepatocellular carcinoma.